Jiang Yupeng, Liu Yuyao, Huang Hong, Zhao Tiantian, Zhao Zengyi, Gao Yawen
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Department of Oncology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Cancer Immunol Immunother. 2025 Feb 1;74(3):78. doi: 10.1007/s00262-024-03926-9.
Microsatellite high instability/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) has an active tumor microenvironment, rendering it more sensitive to immune checkpoint inhibitors. Given that studies involving patients with MSI-H colorectal cancer with RAS mutations are scarce, we explored the effect of RAS mutations on the TME in patients with MSI-H/dMMR cancer and identified potential prognostic factors.
Seventy-five patients diagnosed with MSI-H/dMMR colorectal cancer were retrospectively enrolled and divided into RAS-mutant and -wild-type groups. The expression levels of CD11c dendritic cells, CD4 T cells, CD8 T cells, and regulatory T cell (Treg) markers were detected, and prognostic factors were analyzed.
RAS-mutant MSI-H colorectal patients were more likely to have: (1) higher platelet values; (2) shorter disease-free survival (DFS); (3) lower infiltrated numbers of CD11c dendritic cells, CD4 T lymphocytes, and CD8 T lymphocytes, and higher infiltrated numbers of Foxp3 Treg cells. In MSI-H/dMMR CRC patients: (1) the high CD11c + , CD4 +, and CD8 + cells infiltration group had longer DFS than the low-infiltration group, and Foxp3 + cells infiltration was not significantly correlated with DFS; (2) the RAS mutation status, number of CD11c cells infiltrated, and carbohydrate antigen 19-9 (CA19-9) level were the potential prognostic factors.
RAS mutations in patients with MSI-H/dMMR CRC may reduce the infiltration of CD11c dendritic cells, CD4 T cells, and CD8 T cells, and increase the infiltration of Foxp3 Treg cells to affect the tumor microenvironment of patients. RAS gene status, CD11c + cells infiltration, and CA19-9 level were potential prognostic factors for MSI-H/dMMR CRC.
微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)结直肠癌(CRC)具有活跃的肿瘤微环境,使其对免疫检查点抑制剂更敏感。鉴于涉及RAS突变的MSI-H结直肠癌患者的研究较少,我们探讨了RAS突变对MSI-H/dMMR癌症患者肿瘤微环境的影响,并确定了潜在的预后因素。
回顾性纳入75例诊断为MSI-H/dMMR结直肠癌的患者,并分为RAS突变组和野生型组。检测CD11c树突状细胞、CD4 T细胞、CD8 T细胞和调节性T细胞(Treg)标志物的表达水平,并分析预后因素。
RAS突变的MSI-H结直肠癌患者更有可能出现:(1)血小板值更高;(2)无病生存期(DFS)更短;(3)CD11c树突状细胞、CD4 T淋巴细胞和CD8 T淋巴细胞的浸润数量更低,而Foxp3 Treg细胞的浸润数量更高。在MSI-H/dMMR CRC患者中:(1)CD11c +、CD4 +和CD8 +细胞高浸润组的DFS比低浸润组长,且Foxp3 +细胞浸润与DFS无显著相关性;(2)RAS突变状态、CD11c细胞浸润数量和糖类抗原19-9(CA19-9)水平是潜在的预后因素。
MSI-H/dMMR CRC患者中的RAS突变可能会减少CD11c树突状细胞、CD4 T细胞和CD8 T细胞的浸润,并增加Foxp3 Treg细胞的浸润,从而影响患者的肿瘤微环境。RAS基因状态、CD11c +细胞浸润和CA19-9水平是MSI-H/dMMR CRC的潜在预后因素。